<DOC>
	<DOCNO>NCT00912288</DOCNO>
	<brief_summary>No Dimebon clinical data exist yet patient disease advanced moderate-to-severe stage . Therefore , study evaluates safety efficacy Dimebon patient moderate-to-severe AD receiving exist background therapy memantine .</brief_summary>
	<brief_title>A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer 's Disease</brief_title>
	<detailed_description>This study terminate May 7 , 2010 due modification dimebon development plan follow lack demonstration efficacy complete DIM14 ( CONNECTION ) Study . The study terminate due safety finding . Dimebon well-tolerated clinical trial . Demonstration efficacy dimebon Alzheimer 's disease pending completion ongoing DIM18 ( CONCERT ) Study .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Are men woman â‰¥ 50 year age diagnosis Alzheimers disease . Have MiniMental State Exam 5 14 inclusive . Have take medication memantine ( ie. , Namenda ) least six month prior study . Must caregiver assist patient least five day per week least three hour per day , accompany patient study visit , intimate knowledge patient 's health state personal care . Have take medicine Alzheimers disease memantine ( e.g. , donepezil , rivastigmine , galantamine , tacrine ) within 2 month prior study . Dementia Alzheimers disease . Any medical condition reason interfere ability patient participate complete trial place patient undue risk , judge study doctor .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Alzheimer disease moderate-to-severe memantine safety efficacy</keyword>
</DOC>